The Biotechnology Industry Organization elected new board members last week in conjunction with its annual international convention:
- Joshua Boger, chairman, president, and CEO of Vertex Pharmaceuticals, was elected chairman of the board. He succeeds James Mullen, CEO of Biogen.
- Joseph Scodari, worldwide chairman of Johnson & Johnson’s Pharmaceuticals group, was named vice chair of healthcare.
- Andrew Baum of SemBioSys Genetics was appointed vice chair of food and agriculture, and secretary.
- Mark Skaletsky, chairman, president, and CEO of Trine Pharmaceuticals, was named treasurer.
MSBi Capital, a Montreal-based venture capital fund specializing in the software, semiconductor, medical devices, biopharmaceuticals, cleantech, and advanced technologies industries, last week said that it has added Francois Gauvin and John Elton as partners.
Gauvin, who will also be MSBi Capital's chief financial officer, joins MSBi from the Solidarity Fund QFL, a Quebec-area investment fund for which he managed a $250 million external technology fund portfolio. Elton most recently served as a consultant to McGill University’s Office of Technology Transfer.
Glen Giovanetti has been appointed as leader of Ernst & Young's new Global Biotechnology Center in Boston, E&Y said last week.
Giovanetti relocated to Boston from Northern California, where he was business risk services leader for the Pacific North West Area.
E&Y also said that Scott Sarazen has been appointed to the new position of global markets leader within the center. Sarazen’s previous positions include senior vice president for life sciences with MassDevelopment and director of global planning and development at Genzyme Corporation.